Sunshine Guojian Pharmaceutical Shanghai Co 688336.SS · CNY
Health Care · Shanghai · 🇨🇳 China
33.16
-0.33%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sunshine Guojian Pharmaceutical Shanghai Co
Its shares trade on Shanghai under the ticker 688336.SS. It has been listed since 22 July 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥4.20bn and net income of CN¥2.94bn. At that date it held total assets of CN¥8.96bn and shareholders' equity of CN¥5.86bn.
Sunshine Guojian Pharmaceutical Shanghai Co Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-07-22. Sunshine Guojian Pharmaceutical Shanghai Co Ltd is a China-based company mainly engaged in the research and development, industrialization and commercialization of antibody drugs. Its products are mainly used to treat major diseases such as autoimmune diseases and tumors. The Company’s product, recombinant human type II tumor necrosis factor receptor-antibody fusion protein (trade name: YISAIPU), is a fully human antibody drug used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. The firm mainly conducts its businesses in Mainland China.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 22 Jul 2020
- Employees
- 1,135
- Website
- 3s-guojian.com ↗
Leadership
Pay as last reported
- Mr. Jing LouChairman of the Board, since 2016
- Ms. Yongzhi SunFinance Director, Director, since 2019CN¥952,500
- Mr. Haowen HuangVice President - Research & DevelopmentCN¥1.6m
- Ms. Yanli LiuGeneral Manager, Director, since 2019CN¥1.4m
- Mr. Zhibing WengDirector of Process Development and Pilot Production Department, Senior DirectorCN¥1.3m
- Mr. Qi ZhangSecretary of the Board
- Ms. Dongmei SuDirector
- Mr. Yongli JinIndependent DirectorCN¥136,800
- Mr. Song YouIndependent Director
- Ms. Wei ZhangIndependent DirectorCN¥136,800
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sunshine Guojian Pharmaceutical Shanghai Co Ltd employs 1,135 full-time staff members in Shanghai.
- The company focuses on research and development of antibody drugs for major diseases.
- YISAIPU treats rheumatoid arthritis, ankylosing spondylitis, and psoriasis effectively in patients.
Weaknesses
- The firm mainly conducts its businesses in Mainland China only.
- Sunshine Guojian Pharmaceutical Shanghai Co Ltd has limited geographic diversification currently.
- The company relies heavily on a single trade name product YISAIPU.
Opportunities
- Expanding commercialization of antibody drugs could increase revenue significantly in China.
- Treating autoimmune diseases offers a large potential market for YISAIPU growth.
- Industrialization of new tumor treatments may attract more investors and patients.
Threats
- Competition in the Biotechnology industry could reduce market share for YISAIPU.
- Economic changes in Mainland China might affect the company's operational costs.
- Regulatory changes in Health Care could impact the commercialization of antibody drugs.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.